Zacks Research Issues Positive Estimate for BMRN Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Zacks Research lifted their Q1 2025 earnings estimates for BioMarin Pharmaceutical in a report released on Tuesday, November 19th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings per share of $0.60 for the quarter, up from their previous forecast of $0.59. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $2.47 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q2 2025 earnings at $0.68 EPS, Q1 2026 earnings at $0.76 EPS, Q2 2026 earnings at $0.83 EPS and FY2026 earnings at $3.36 EPS.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by ($0.23). The company had revenue of $746.00 million during the quarter, compared to analysts' expectations of $703.37 million. BioMarin Pharmaceutical had a return on equity of 8.53% and a net margin of 11.71%. BioMarin Pharmaceutical's revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share.

A number of other analysts have also issued reports on the stock. Stifel Nicolaus reduced their price target on shares of BioMarin Pharmaceutical from $115.00 to $87.00 and set a "buy" rating for the company in a research report on Tuesday, September 17th. StockNews.com raised shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Thursday, August 8th. Piper Sandler raised their price objective on shares of BioMarin Pharmaceutical from $107.00 to $122.00 and gave the company an "overweight" rating in a research report on Thursday, September 5th. Citigroup cut their price objective on shares of BioMarin Pharmaceutical from $93.00 to $81.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Finally, Barclays cut their price objective on shares of BioMarin Pharmaceutical from $110.00 to $86.00 and set an "overweight" rating on the stock in a research report on Friday, October 4th. Seven investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average target price of $94.20.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN opened at $62.56 on Thursday. The company has a 50 day simple moving average of $69.08 and a 200-day simple moving average of $78.70. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62. The firm has a market capitalization of $11.92 billion, a price-to-earnings ratio of 37.46, a price-to-earnings-growth ratio of 0.63 and a beta of 0.31. BioMarin Pharmaceutical has a 52-week low of $61.15 and a 52-week high of $99.56.

Insider Buying and Selling at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Charles Greg Guyer sold 5,278 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $66.37, for a total value of $350,300.86. Following the sale, the executive vice president now owns 68,909 shares of the company's stock, valued at $4,573,490.33. The trade was a 7.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.85% of the company's stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the business. Erste Asset Management GmbH bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth about $48,527,000. Principal Financial Group Inc. grew its holdings in shares of BioMarin Pharmaceutical by 1,858.6% in the 2nd quarter. Principal Financial Group Inc. now owns 649,460 shares of the biotechnology company's stock worth $53,470,000 after purchasing an additional 616,301 shares during the last quarter. Vestal Point Capital LP bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth about $28,116,000. Assenagon Asset Management S.A. grew its holdings in shares of BioMarin Pharmaceutical by 11,107.4% in the 2nd quarter. Assenagon Asset Management S.A. now owns 352,474 shares of the biotechnology company's stock worth $29,019,000 after purchasing an additional 349,329 shares during the last quarter. Finally, Clearline Capital LP bought a new stake in shares of BioMarin Pharmaceutical in the 3rd quarter worth about $22,477,000. Institutional investors own 98.71% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.